Over the past 12 months, $CRNX generated 8 mentions from 4 distinct FinTwit voices, with biotech analyst Adam Feuerstein (@adamfeuerstein) accounting for 5 of those mentions. The first mention appeared on September 25, 2025, and discussion continued through July 2026. Crinetics Pharmaceuticals, a commercial-stage biotech company, became the subject of significant discussion following acquisition activity, with Feuerstein noting the company's stock had underperformed the broader biotech index ($XBI) before the deal.